Bladder cancer is one of the most frequent urological malignancies, with a high recurrence rate that requires frequent and careful follow-up. However, traditional urinary cytology, while a noninvasive and widely used tool, suffers from limited sensitivity, particularly for low-grade forms.
In this context, artificial intelligence (AI) is opening new horizons, enabling more accurate and standardized analysis of cells in urine. Among the companies that are driving this transformation, Hospitex International stands out for a particularly integrated and clinically oriented approach.

A central element of Hospitex's innovation is the Urine24 service, a home urine cytology solution with centralized analysis. The patient collects the specimen at home, sends it to the lab, and receives the results on e-mail quickly. But what makes the system revolutionary is its technological back-end: slides prepared with CYTOfast technology, analyzed according to the international standard of The Paris System.

Reliable diagnosis always starts with a quality sample. Hospitex has developed its own thin-layer preparation technology-the aforementioned CYTOfast-that takes advantage of the Nephelometric Smart Technology (NST) system. This method results in clean, uniform slides that are perfect for reading by both an experienced pathologist and an AI algorithm. With this approach, the data that feed the AI algorithms are more accurate and reproducible, making automated analyses more reliable and clinically applicable.

Since 2022, Hospitex has been part of the Ikonisys Group, now Aliko Scientific, which specializes in automated robotic microscopy solutions. Integration with instruments such as theIkoniscope20, a high-resolution automated microscope, allows FISH (fluorescent in situ hybridization) techniques to be applied in a fully automated way, further improving the accuracy of cytogenetic diagnosis. This synergy may make possible a fully automated diagnostic pathway from slide preparation to molecular analysis.

A further strength of Hospitex's strategy is the ability to integrate these technologies into daily practice, building true diagnostic supply chains, thanks to partners such as Pathoxphere.

This approach allows not only a more accurate diagnosis, but also a widespread dissemination of prevention, through hospital and non-hospital channels. A true paradigm shift for territorial medicine.

In bladder cancer, early diagnosis and ongoing monitoring are critical to improving therapeutic outcomes and reducing the clinical and economic impact of the disease. Hospitex International's approach stands as one of the most comprehensive answers available in the diagnostic landscape today. It is no longer just a matter of "helping" the physician with AI, but of rethinking the entire diagnostic process, making it more efficient, more accessible and, above all, more accurate.